NCT06674252Recruiting
A Study on the Improvement of Postoperative Symptoms and Survival Benefits of Modified Bufei Decoction in Elderly Patients With Lung Cancer Undergoing Radical Surgery
A Randomized Controlled Multicenter Study on the Improvement of Postoperative Symptoms and Survival Benefits of Modified Bufei Decoction in Elderly Patients With Lung Cancer Undergoing Radical Surgery
Source: ClinicalTrials.gov · Last updated 27 Jan 2026
Brief summary (registry, in English)
This is a randomized double-blind placebo-controlled phase II clinical study that included patients with symptoms such as cough, shortness of breath, and fatigue after lung cancer resection surgery. They were given orally modified Bufei Tang granules twice a day for 28 days, with one packet taken orally with water. Using the MDASI-TCM symptom scoring system, evaluate the scores of symptoms such as cough, shortness of breath, and fatigue before and after the experiment, and calculate the difference in scores between the control group and the experimental group before and after the experiment.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 174 (estimated)
- First submitted
- 4 Nov 2024
- Start date
- 13 Jun 2025
- Primary completion date
- Sept 2027
- Lead sponsor
- Peking University Cancer Hospital & Institute
- Diseases
- Lung cancer
- NCT number
- NCT06674252
What you commit to
- Study type: Interventional
- Planned participants: 174
- From 13 Jun 2025 to the primary completion date, Sept 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Patients with severe pulmonary infections. ⑵. Patients with mental illness. ⑶. Patients with depression.
Who the study is looking for
- Patients with postoperative lung cancer who have clear histological or cytological diagnosis.
- Age ≥ 65 years old, both male and female are eligible. According to the MDASI-TCM scale evaluation, any of the three symptoms of cough, fatigue, and shortness of breath should score ≥ 4 points, or the sum of the three should score ≥ 6 points.
- The heart function is basically normal; ALT/AST is within 2 times the normal value; SCr is within the normal range.
- Traditional Chinese medicine syndrome differentiation is characterized by deficiency of both lungs and kidneys.
Age in the registry: 65 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Beijing Cancer Hospital Coordinator of this site? Confirm its status | Beijing | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.